The Pharmaceuticals & Medical Products Practice works with a diverse spectrum of organizations, including companies in ethical and over-the-counter (OTC) pharmaceuticals, medical equipment, devices and supplies, diagnostics, biotechnology, and animal health. We help clients address a full range of strategic, competitive, and operational issues.

We advise clients on opportunities in licensing and alliances, portfolio management, and existing and emerging therapeutic areas and technologies. Because R&D pipelines and the search for the next blockbuster are essential to continued strong performance, we help clients develop sound R&D strategies. We also address issues such as sales force management, direct-to-consumer advertising, global product launches, and life cycle management as patents expire.

As more prescription drugs become available over the counter, we help clients assess their opportunities, explore partnerships with consumer product companies, understand the regulatory hurdles, and measure the impact on prescription sales.

The mapping of the human genome is leading the charge for new drugs and treatment regimens. We help pharmaceutical biotechnology companies identify promising technologies, new entities, and improved therapies based on genomics, informatics, proteomics, and other biotech advances. We also assist clients in developing partner, acquisition, and licensing strategies.

The medical products and diagnostics industries are large and diverse, ranging from simple supply items to life-saving cardiovascular products. We work with clients to identify and pursue new products, technologies, and businesses, as well as to chart strategies for global leadership, including acquisitions.

Many human pharmaceuticals also have animal (farm and companion) health applications. We help clients explore animal markets for their human products. We also develop portfolio strategies and R&D programs to explore new drugs and formulations that meet animals' special requirements.